Holen Sie sich die Stockscreener-App
15.86
1.99%
0.31
Schlusskurs vom Vortag:
$15.55
Offen:
$15.46
24-Stunden-Volumen:
28,213
Relative Volume:
0.18
Marktkapitalisierung:
$143.48M
Einnahmen:
$123.24M
Nettoeinkommen (Verlust:
$136.00K
KGV:
-793.00
EPS:
-0.02
Netto-Cashflow:
$-148.99M
1W Leistung:
+6.59%
1M Leistung:
-4.80%
6M Leistung:
+46.18%
1J Leistung:
-8.85%
1-Tages-Spanne:
$15.46
$16.30
1-Wochen-Bereich:
$14.50
$16.30
52-Wochen-Spanne:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Firmenname
Seres Therapeutics Inc
Sektor
Branche
Telefon
617 945 9626
Adresse
200 SIDNEY STREET, CAMBRIDGE, MA
Vergleichen Sie MCRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
15.86 | 140.67M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-08 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-04-21 | Eingeleitet | JP Morgan | Neutral |
| 2021-07-23 | Herabstufung | Goldman | Neutral → Sell |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-03-05 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-11 | Hochstufung | Jefferies | Hold → Buy |
| 2019-04-30 | Eingeleitet | Jefferies | Hold |
| 2018-10-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2017-10-13 | Eingeleitet | Oppenheimer | Outperform |
| 2017-08-04 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-01 | Bestätigt | FBR & Co. | Outperform |
| 2016-08-12 | Bestätigt | FBR Capital | Outperform |
| 2016-08-01 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Bestätigt | H.C. Wainwright | Buy |
| 2016-07-29 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-03-30 | Eingeleitet | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | Guggenheim | Buy |
| 2016-01-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-10-22 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-07-21 | Eingeleitet | Goldman | Neutral |
| 2015-07-21 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Seres Therapeutics Inc Aktie (MCRB) Neueste Nachrichten
Why Seres Therapeutics Inc. stock is in analyst buy zoneBearish Engulfing Patterns & Big Gains Small Capital - ulpravda.ru
Seres Therapeutics publishes new insights on VOWST mechanism By Investing.com - Investing.com Nigeria
Seres Therapeutics expands board, appoints new director - MSN
Seres Therapeutics publishes new insights on VOWST mechanism - Investing.com
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy - Yahoo Finance
Why Seres Therapeutics Inc. stock is rated strong buyInterest Rate Changes & Minimal Risk High Reward - bollywoodhelpline.com
Seres Therapeutics (NASDAQ:MCRB) Stock Price Passes Below 50-Day Moving AverageHere's Why - MarketBeat
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
How Seres Therapeutics Inc. stock responds to policy changesGlobal Markets & Verified Entry Point Detection - Улправда
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era - FinancialContent
Will Seres Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Report & Safe Entry Point Identification - DonanımHaber
Can Seres Therapeutics Inc. (1S90) stock stage a strong rebound this quarterMarket Volume Report & Fast Gain Swing Alerts - DonanımHaber
Why analysts remain bullish on Seres Therapeutics Inc. stockRate Cut & Daily Profit Focused Stock Screening - DonanımHaber
Is Seres Therapeutics Inc. stock affected by interest rate hikesCPI Data & Weekly Return Optimization Alerts - Улправда
Will Seres Therapeutics Inc. stock gain from government policiesJuly 2025 Market Mood & Weekly Top Stock Performers List - Улправда
Seres Therapeutics Cuts Costs to Extend Cash Runway - MSN
Head-To-Head Contrast: Castle Biosciences (NASDAQ:CSTL) versus Seres Therapeutics (NASDAQ:MCRB) - Defense World
North America Human Microbiome Market Size & Growth Forecast to 2031 - MarketsandMarkets
Guidance Update: How Seres Therapeutics Inc 1S90 stock compares with market leaders2025 Biggest Moves & Long-Term Growth Stock Strategies - moha.gov.vn
Published on: 2025-12-13 20:57:20 - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Above 50 Day Moving AverageHere's What Happened - MarketBeat
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN
Seres Therapeutics, Inc. (MCRB) 5.04% in After-hours: What’s Driving the Move? - Stocks Telegraph
Seres Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving Average – Here’s What Happened - Defense World
Seres Therapeutics (MCRB) Price Target Increased by 31.25% to 21.42 - Nasdaq
What risks investors should watch in Seres Therapeutics Inc. stockQuarterly Growth Report & Accurate Intraday Trading Signals - Newser
Seres Therapeutics (NASDAQ:MCRB) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat
Will Seres Therapeutics Inc. (1S90) stock outperform foreign stocksWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Will Seres Therapeutics Inc. (1S90) stock beat value stocks2025 Year in Review & Verified Chart Pattern Signals - Newser
What market sentiment indicators show for Seres Therapeutics Inc. (1S90) stock2025 Institutional Moves & Free Daily Entry Point Trade Alerts - Newser
Is Seres Therapeutics Inc. stock dividend yield sustainablePortfolio Update Report & Growth Oriented Trade Recommendations - Newser
Is Seres Therapeutics Inc. stock positioned for long term growth2025 Support & Resistance & Growth Focused Stock Pick Reports - Newser
Seres Therapeutics (MCRB) Stock Analysis Report | Financials & Insights - Benzinga
Volatility Watch: Why Seres Therapeutics Inc. stock is rated strong buyJuly 2025 Review & High Accuracy Trade Alerts - moha.gov.vn
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving AverageShould You Sell? - MarketBeat
A look into Seres Therapeutics Inc (MCRB)’s deeper side - Setenews
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - The Manila Times
Seres Therapeutics (Nasdaq: MCRB) to join Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Seres Therapeutics Inc Stock Analysis and ForecastHead and Shoulders Patterns & Big Gains Low Cost - earlytimes.in
What analysts say about Seres Therapeutics Inc stockMACD Histogram Signals & Budget Friendly Capital Growth - earlytimes.in
Should You Watch Rane Engine Valve Limited for Sector Rotation UpsideWeekly Market Snapshot & Free Stock Market Mentorship Programs - earlytimes.in
Can Poonawalla Fincorp Limited Deliver Consistent Free Cash FlowsMarket Depth Overview & Swing Trade Smarter With Data Insights - earlytimes.in
Seres Therapeutics, Inc. (MCRB) -17.5% in Normal Trading: Shares Dip Amid Recent Insider Sales - Stocks Telegraph
Finanzdaten der Seres Therapeutics Inc-Aktie (MCRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):